Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: Sequential tamoxifen-exemestane and upfront anastrozole

C. Skedgel; D. Rayson; R. Dewar; T. Younis

doi:10.1007/s10549-006-9299-4

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: Sequential tamoxifen-exemestane and upfront anastrozole

C. Skedgel, D. Rayson, R. Dewar, T. Younis

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	325-333
Number of pages	9
Journal	Breast Cancer Research and Treatment
Volume	101
Issue number	3
DOIs	https://doi.org/10.1007/s10549-006-9299-4
Publication status	Published - Mar 2007

ASJC Scopus Subject Areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-006-9299-4

Cite this

@article{d59fd99fdaf44fd88afb2571cc9db5f9,

title = "Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: Sequential tamoxifen-exemestane and upfront anastrozole",

author = "C. Skedgel and D. Rayson and R. Dewar and T. Younis",

note = "Funding Information: This evaluation was funded by a grant from the Capital Health Research Fund. A subsequent project adapted the model framework for an evaluation from the Belgian perspective with the support of Pfizer Belgium.",

year = "2007",

month = mar,

doi = "10.1007/s10549-006-9299-4",

language = "English",

volume = "101",

pages = "325--333",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "3",

}

TY - JOUR

T1 - Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women

T2 - Sequential tamoxifen-exemestane and upfront anastrozole

AU - Skedgel, C.

AU - Rayson, D.

AU - Dewar, R.

AU - Younis, T.

N1 - Funding Information: This evaluation was funded by a grant from the Capital Health Research Fund. A subsequent project adapted the model framework for an evaluation from the Belgian perspective with the support of Pfizer Belgium.

PY - 2007/3

Y1 - 2007/3

UR - http://www.scopus.com/inward/record.url?scp=33846475483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846475483&partnerID=8YFLogxK

U2 - 10.1007/s10549-006-9299-4

DO - 10.1007/s10549-006-9299-4

M3 - Article

C2 - 16897433

AN - SCOPUS:33846475483

SN - 0167-6806

VL - 101

SP - 325

EP - 333

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 3

ER -

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: Sequential tamoxifen-exemestane and upfront anastrozole

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this